Relationship Between FDG Uptake and Expressions of Glucose Transporter Type 1, Type 3, and Hexokinase-II in Reed-Sternberg Cells of Hodgkin Lymphoma

$79.00 plus tax (Refund Policy)

Buy Article:

Abstract:

Reed-Sternberg (R-S) cells are the main tumor cells of Hodgkin lymphoma (HL). HL has been reported to demonstrate a high level of [18F]2-fluoro-2-deoxy-D-glucose (FDG) uptake, but the determinant of FDG uptake for HL has not been well elucidated. Thus, we investigated the relationship of FDG uptake and the expressions of glucose transporter type 1 (Glut-1), glucose transporter type 3 (Glut-3), and hexokinase II (HK-II) in R-S cells of HL. There were 25 tissue-proven HL patients from January 2003 to July 2007 in our hospital. Of the 25 HL patients, 4 cases obtained by surgical excision were included in the present study. The immunostaining for Glut-1, Glut-3, and HK-II was conducted in the excised masses. The maximum standardized uptake values (maxSUVs) were compared to the expressions of Glut-1, Glut-3, and HK-II. Three HL patients (mixed cellularity = 2 and nodular sclerosis = 1) demonstrated moderate-strong expressions of Glut-1 in almost all R-S cells, and of these three HL patients, two underwent FDG-PET, which revealed a high level of maxSUVs (7.7, 6.5) in the corresponding HL lesions. One HL patient (lymphocyte depletion) showed weak Glut-1 expressions in only 10% of R-S cells, but no FDG-PET study was available. The expressions of Glut-3 and HK-II were various in all four HL patients, and no specific correlations with FDG uptake were found. In conclusion, high expressions of Glut-1 in R-S cells may play a crucial role for the high FDG uptake in Hodgkin lymphoma.

Keywords: FDG-PET; Glucose transporter; Hexokinase; Hodgkin lymphoma

Document Type: Research Article

DOI: http://dx.doi.org/10.3727/096504009787721177

Publication date: January 1, 2009

More about this publication?
  • Formerly: Oncology Research Incorporating Anti-Cancer Drug Design
    Oncology Research Featuring Preclinical and Clincal Cancer Therapeutics publishes research of the highest quality that contributes to an understanding of cancer in areas of molecular biology, cell biology, biochemistry, biophysics, genetics, biology, endocrinology, and immunology, as well as studies on the mechanism of action of carcinogens and therapeutic agents, reports dealing with cancer prevention and epidemiology, and clinical trials delineating effective new therapeutic regimens.
Related content

Tools

Favourites

Share Content

Access Key

Free Content
Free content
New Content
New content
Open Access Content
Open access content
Subscribed Content
Subscribed content
Free Trial Content
Free trial content
Cookie Policy
X
Cookie Policy
ingentaconnect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more